3D Genome: Gene Regulation and Disease
joint with Epigenetics and Human Disease
Organizer(s): Bing Ren, Ana Pombo and Joseph R. EckerDate: March 17 - 21, 2019
Location: Fairmont Banff Springs, Banff, AB, Canada
Transcription of the eukaryotic genome is not only driven by the cis regulatory elements embedded in the linear DNA sequence but also by the way chromosomes fold in the three-dimensional (3D) nuclear space. Growing evidence has pointed to a key role of the 3D genome architecture in gene regulation and human disease. However, the details of dynamic chromatin organization in different cell types remain opaque. Additionally, how chromatin organization shapes the gene regulatory program and influences disease pathogenesis has not been fully elucidated. The major objective of this conference is to accelerate the study of 3D genome organization particularly with regard to gene regulation and human disease. The conference program will highlight recent technological advances, such as omics-based and imaging-based technologies. The conference will also discuss emerging concepts of chromatin organization and its role in cancer and other human diseases. Finally, the conference program will provide workshops and tutorials on the latest computational tools and data resources for 3D genome analysis. Because epigenetic processes such as chromatin remodeling and DNA methylation are intimately linked to the 3D genome architecture, this conference will be held jointly with the Keystone Symposia conference on “Epigenetics and Human Disease”, further enhancing the goal to stimulate cross disciplinary interactions among researchers from genomics, epigenomics, computational biology, cell biology and molecular biology fields.
Scholarship Deadline: November 29 2018
Discounted Abstract Deadline: November 29 2018
Abstract Deadline: December 12 2018
Discounted Registration Deadline: January 22 2019
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA236117-01
Funding for this conference was made possible (in part) by 1R13CA236117-01 from the National Institutes of Health, supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director.The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.